SwePub
Sök i LIBRIS databas

  Extended search

L773:1538 7933
 

Search: L773:1538 7933 > (2005-2009) > Treatment of severe...

  • Borel-Derlon, A. (author)

Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin (R)): a prospective study of 50 patients

  • Article/chapterEnglish2007

Publisher, publication year, extent ...

  • Elsevier BV,2007

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:6fd08d0f-4331-473d-a792-53d80b44db15
  • https://lup.lub.lu.se/record/662539URI
  • https://doi.org/10.1111/j.1538-7836.2007.02562.xDOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Background and objectives: A plasma-derived von Willebrand factor (VWF) concentrate with low factor VIII (FVIII) content was specifically developed to treat von Willebrand disease (VWD). Efficacy and safety were investigated by merging the results of two comparable protocols conducted prospectively in 5 European and 12 French centers. Methods and results: Fifty patients with clinically severe VWD (72% had VWF ristocetin cofactor activity less than 10 IU dL(-1) and 46% had FVIII < 20 IU dL(-1)) were treated with the concentrate as the only therapy, except for clinical situations requiring a priming dose of FVIII to rapidly correct an intrinsic coagulation defect. A total of 139 spontaneous bleeding episodes were treated; only 53 (38%) needed a concomitant FVIII dose. Outcome was excellent or good in 89% of the episodes. Forty-four patients underwent 108 surgical or invasive procedures. Outcome was excellent or good in 95 scheduled procedures (only VWF was infused) and 13 emergency procedures (a priming FVIII dose was co-administered with the first VWF infusion). There were no thrombotic complications and none of the 18 patients with type 3 VWD developed anti-VWF or anti-FVIII antibodies. Conclusions. This concentrate safely and effectively provides hemostasis in patients with clinically severe VWD.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Federici, A. B. (author)
  • Roussel-Robert, V. (author)
  • Goudemand, J. (author)
  • Lee, C. A. (author)
  • Scharrer, I. (author)
  • Rothschild, C. (author)
  • Berntorp, ErikLund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups(Swepub:lu)medf-ebe (author)
  • Henriet, C. (author)
  • Tellier, Z. (author)
  • Bridey, F. (author)
  • Mannucci, P. M. (author)
  • Klinisk koagulationsmedicin, MalmöForskargrupper vid Lunds universitet (creator_code:org_t)

Related titles

  • In:Journal of Thrombosis and Haemostasis: Elsevier BV5:6, s. 1115-11241538-79331538-7836

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view